Cargando…

Training patients for self‐administration of a new subcutaneous C1‐inhibitor concentrate for hereditary angioedema

AIMS: The aim of this study was to provide recommendations for training patients with hereditary angioedema, based on nursing clinical trial experience, to self‐administer subcutaneous C1‐INH (C1‐INH[SC]) used as routine prophylaxis. BACKGROUND: A volume‐reduced, subcutaneous C1‐INH concentrate (C1‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murphy, Elyse, Donahue, Christine, Omert, Laurel, Persons, Stephanie, Tyma, Thomas J., Chiao, Joseph, Lumry, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279717/ https://www.ncbi.nlm.nih.gov/pubmed/30534402 http://dx.doi.org/10.1002/nop2.194

Ejemplares similares

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020)

Hereditary Angioedema: The Economics of Treatment of an Orphan Disease
por: Lumry, William Raymond
Publicado: (2018)

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
por: Craig, Timothy, et al.
Publicado: (2017)

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate
por: Zuraw, B. L., et al.
Publicado: (2015)

Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
por: Zhang, Ying, et al.
Publicado: (2018)

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019)

Patterns of on-demand medication use in patients with hereditary angioedema treated long-term with prophylactic subcutaneous C1-inhibitor
por: Levy, Donald S., et al.
Publicado: (2019)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
por: Levy, Donald, et al.
Publicado: (2020)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
por: Anderson, John, et al.
Publicado: (2021)

Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
por: Hsu, Florence Ida, et al.
Publicado: (2022)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Correction: Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
por: Hsu, Florence Ida, et al.
Publicado: (2022)

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema
por: Gower, Richard G., et al.
Publicado: (2021)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Self-administration of a novel subcutaneous bradykinin b(2) receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
por: Santucci, Stephanie, et al.
Publicado: (2014)

Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology
por: Sinnathamby, Evan S., et al.
Publicado: (2023)

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2014)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Hereditary Angioedema: Not An Allergy
por: Bhivgade, Sanjay, et al.
Publicado: (2012)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

Pediatric hereditary angioedema
por: MacGinnitie, Andrew J
Publicado: (2014)

Hereditary angioedema in childhood
por: Ahn, Young Min
Publicado: (2020)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

TRAUMATIC “ANGIOEDEMA”: EXTENSIVE SUBCUTANEOUS EMPHYSEMA MASQUERADING AS ANGIOEDEMA
por: Khakwani, Z., et al.
Publicado: (2022)

Hereditary Angioedema Consensus 2010
por: Bowen, Tom
Publicado: (2010)

Bradykinin and the Pathogenesis of Hereditary Angioedema
por: Kaplan, Allen P
Publicado: (2011)

The Search for Biomarkers in Hereditary Angioedema
por: Kaplan, Allen P., et al.
Publicado: (2017)

Improving the Management of Hereditary Angioedema
por: Giavina-Bianchi, Pedro, et al.
Publicado: (2018)

Pediatric hereditary angioedema: an update
por: Sabharwal, Geetika, et al.
Publicado: (2017)

Are pediatricians familiar with hereditary angioedema?
por: Chong-Neto, Herberto José, et al.
Publicado: (2023)

C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option
por: Longhurst, H J, et al.
Publicado: (2007)

Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
por: Feussner, Annette, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vb36fmn89in7923u66g2liiin1